{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:21:17Z","timestamp":1792239677499,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd009081","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000}}],"reference-count":179,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009081.pub2","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T03:45:04Z","timestamp":1612583104000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia"],"prefix":"10.1002","volume":"2021","author":[{"given":"Carole","family":"Parsons","sequence":"additional","affiliation":[{"name":"School of Pharmacy; Queen's University Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Yin","family":"Lim","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology; Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia; Shah Alam Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Loy","sequence":"additional","affiliation":[{"name":"Brain and Mind Centre and Sydney School of Public Health, Faculty of Medicine; University of Sydney; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"McGuinness","sequence":"additional","affiliation":[{"name":"Centre for Public Health; Queen's University Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Passmore","sequence":"additional","affiliation":[{"name":"Centre for Public Health; Queen's University Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A","family":"Ward","sequence":"additional","affiliation":[{"name":"Monash Aging Research Center; The Kingston Centre; Cheltenham Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel","family":"Hughes","sequence":"additional","affiliation":[{"name":"School of Pharmacy; Queen's University Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"10.1002\/14651858.CD009081.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer's disease","volume":"366","author":"Howard","year":"2012","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1002\/14651858.CD009081.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S1474-4422(15)00258-6","article-title":"Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer's disease (DOMINO-AD) trial: secondary and post-hoc analyses","volume":"14","author":"Howard","year":"2015","journal-title":"The Lancet Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1745-6215-10-57","article-title":"DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT","volume":"10","author":"Jones","year":"2009","journal-title":"Trials"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/gps.4583","article-title":"Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's Disease (the DOMINO-AD trial)","volume":"32","author":"Knapp","year":"2017","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0005|cit5","unstructured":"Email to: C Parsons"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0006|cit6","unstructured":"Janssen Research and Development Clinical Study Report Synopsis GAL ITA 2; Phase III JNJ-17335630-AAD (Galantamine) The Yale University Open Data Access (YODA) Project."},{"key":"10.1002\/14651858.CD009081.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3233\/JAD-2011-110134","article-title":"Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's Disease: a randomized, double blind, placebo controlled withdrawal trial","volume":"26","author":"Scarpini","year":"2011","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/156720511797633205","article-title":"Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment","volume":"8","author":"Gaudig","year":"2011","journal-title":"Current Alzheimer Research"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0009|cit9","unstructured":"Janssen Research Foundation Safety and efficacy of galantamine during its withdrawal in the treatment of Alzheimer's Disease Clinical Research Report"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jamda.2015.08.019","article-title":"A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease","volume":"17","author":"Hermann","year":"2016","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","article-title":"The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease","volume":"63","author":"Holmes","year":"2004","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3233\/JAD-180159","article-title":"Effectiveness of anti-dementia drugs in extremely severe Alzheimer's disease: a 12-week, multicenter, randomized, single-blind study","volume":"63","author":"Hong","year":"2018","journal-title":"Journal of Alsheimer's Disease"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2165\/00023210-200620040-00005","article-title":"Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's Disease","volume":"20","author":"Johannsen","year":"2006","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/S0924-977X(03)92240-1","article-title":"Donepezil-treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: results from a randomised, placebo-controlled trial","volume":"13","author":"Kozubski","year":"2003","journal-title":"European Neuropsychopharmacology"},{"issue":"4S Part 23","key":"10.1002\/14651858.CD009081.pub2-BIB0015|cit15","first-page":"S794","article-title":"Cessation versus continuation of 12 months galantamine therapy in patients with Alzheimer's disease: a randomised, double blind, placebo controlled withdrawal trial","volume":"7","author":"Adami","year":"2011","journal-title":"Alzheimer's and Dementia"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10198-006-0355-0","article-title":"Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain","volume":"7","author":"Antonanzas","year":"2006","journal-title":"European Journal of Health Economics"},{"issue":"5","key":"10.1002\/14651858.CD009081.pub2-BIB0017|cit17","first-page":"425","article-title":"When should one stop cholinesterase inhibitors in patients with Alzheimer's disease?","volume":"26","author":"Bogardus","year":"2001","journal-title":"Journal of Psychiatry and Neuroscience"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amjopharm.2009.04.002","article-title":"Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia","volume":"7","author":"Daiello","year":"2009","journal-title":"The American Journal of Geriatric Pharmacotherapy"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S469","DOI":"10.1016\/S0197-4580(04)81550-1","article-title":"Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits","volume":"25","author":"Doody","year":"2004","journal-title":"Neurobiology of Aging"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archneur.60.6.843","article-title":"Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial","volume":"60","author":"Farlow","year":"2003","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0021|cit21","first-page":"330","article-title":"Donepezil has significant benefits on behavior in patients with severe Alzheimer's Disease","volume":"1","author":"Feldman","year":"2003","journal-title":"American Psychiatric Association 2003 Annual Meeting Research Abstracts"},{"issue":"Suppl A","key":"10.1002\/14651858.CD009081.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1016\/S0149-2918(01)80162-4","article-title":"Switching previous therapies for Alzheimer's Disease to galantamine","volume":"23","author":"Ferris","year":"2001","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD009081.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1368-5031.2006.00970.x","article-title":"Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting","volume":"60","author":"Frankfort","year":"2006","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/156720511797633205","article-title":"Effects of galantamine in Alzheimer's Disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment","volume":"8","author":"Gaudig","year":"2011","journal-title":"Current Alzheimer Reserach"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0025|cit25","first-page":"S592","article-title":"Effectiveness of galantamine in patients with mild-to-moderate dementia: 12 months' outcome data","volume":"8","author":"Gaudig","year":"2012","journal-title":"Alzheimer's & Dementia"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0011-393X(03)00059-6","article-title":"Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on","volume":"64","author":"Grossberg","year":"2003","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/gps.2607","article-title":"Determining the minimum clinically important differences for outcomes in the DOMINO trial","volume":"26","author":"Howard","year":"2011","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"23","key":"10.1002\/14651858.CD009081.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMc1204656","article-title":"Discontinuing donepezil or starting memantine for Alzheimer's disease","volume":"366","author":"Howard","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1447-0594.2009.00519.x","article-title":"Two cases of discontinuation syndrome following cessation of memantine","volume":"9","author":"Kwak","year":"2009","journal-title":"Geriatrics & Gerontology International"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1741-6612.2011.00564.x","article-title":"Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease","volume":"31","author":"Le Couteur","year":"2012","journal-title":"Australasian Journal on Ageing"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0031|cit31","first-page":"S45","article-title":"Pragmatic randomized trial of continuing cholinesterase inhibitors among indeterminate responders","volume":"18","author":"Maclure","year":"2009","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"5","key":"10.1002\/14651858.CD009081.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.amjopharm.2011.08.004","article-title":"Discontinuation of acetylcholinesterase inhibitor treatment in the nursing home","volume":"9","author":"Mansour","year":"2011","journal-title":"The American Journal of Geriatric Pharmacotherapy"},{"issue":"15 Supplement","key":"10.1002\/14651858.CD009081.pub2-BIB0033|cit33","first-page":"P2.8","article-title":"Cholinesterase inhibitor taper worsens symptoms in patients with Parkinson's disease","volume":"92","author":"Moo","year":"2019","journal-title":"Neurology"},{"issue":"Suppl A","key":"10.1002\/14651858.CD009081.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/S0149-2918(01)80161-2","article-title":"Overview","volume":"23","author":"Morris","year":"2001","journal-title":"Clinical Therapeutics"},{"issue":"Suppl A","key":"10.1002\/14651858.CD009081.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1016\/S0149-2918(01)80166-1","article-title":"Panel discussion: recommendations for prescribers","volume":"23","author":"Morris","year":"2001","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/pds.1613","article-title":"Prevalence of cholinesterase inhibitors in subjects with dementia in Europe","volume":"17","author":"Pariente","year":"2008","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0037|cit37","first-page":"Se70","article-title":"A long-term, open-label extension study evaluating the safety of extended-release memantine (28 mg) in patients with moderate to severe Alzheimer's disease","volume":"7","author":"Perhach","year":"2011","journal-title":"Alzheimer's & Dementia"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0038|cit38","first-page":"313","article-title":"Sudden discontinuation of anti-dementia drugs in moderate and severe Alzheimer's disease in a residency for dependent elderly people: a longitudinal descriptive pilot study","volume":"70","author":"Peyro Saint-Paul","year":"2015","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/archneur.61.2.252","article-title":"The cognitive benefits of galantamine are sustained for at least 36 months","volume":"61","author":"Raskind","year":"2004","journal-title":"Archives of Neurology"},{"issue":"S2","key":"10.1002\/14651858.CD009081.pub2-BIB0040|cit40","first-page":"354","article-title":"Predictors of outcome in patients with mild to moderate Alzheimer's disease treated with galantamine","volume":"18","author":"Richarz","year":"2011","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.71.5.589","article-title":"Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial","volume":"71","author":"Rockwood","year":"2001","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/gps.1864","article-title":"Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months","volume":"23","author":"Rockwood","year":"2008","journal-title":"International Journal of Geriatic Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0043|cit43","first-page":"S788","article-title":"Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study","volume":"7","author":"Schauble","year":"2011","journal-title":"Alzheimer's & Dementia"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0044|cit44","first-page":"S665","article-title":"Predictors to long-term treatment response to galantamine","volume":"7","author":"Schauble","year":"2011","journal-title":"Alzheimer's & Dementia"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S1041610211002389","article-title":"Could cholinesterase inhibitors be harmful over the long term?","volume":"24","author":"Schneider","year":"2012","journal-title":"International Psychogeriatrics"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0046|cit46","first-page":"262","article-title":"Effects of continuous, interrupted and delayed galantamine treatment on long-term cognitive function in patients with advanced-moderate Alzheimer's disease","volume":"8","author":"Schwalen","year":"2004","journal-title":"The Journal of Nutrition, Health and Aging"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/gps.811","article-title":"Discontinuation syndrome following donepezil cessation","volume":"18","author":"Singh","year":"2003","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1017\/S1041610208007011","article-title":"Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice","volume":"20","author":"Umegaki","year":"2008","journal-title":"International Psychogeriatrics"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/gps.1979","article-title":"Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease","volume":"23","author":"Waldemar","year":"2008","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"101","key":"10.1002\/14651858.CD009081.pub2-BIB0050|cit50","first-page":"1","article-title":"Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM)","volume":"19","author":"Soler","year":"2019","journal-title":"BMC Geriatrics"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0051|cit51","unstructured":"Cholinesterase inhibitor discontinuation (CID)"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0006-3223(88)90038-8","article-title":"Cornell Scale for Depression in Dementia","volume":"23","author":"Alexopoulos","year":"1988","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0053|cit53","unstructured":"Alzheimer's Disease International World Alzheimer Report London, UK: Alzheimer's Disease International; 2009"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0054|cit54","unstructured":"Alzheimer's Disease International World Alzheimer Report London (UK): Alzheimer's Disease International; 2016"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0055|cit55","volume-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0047-6374(01)00314-1","article-title":"Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine","volume":"122","author":"Amici","year":"2001","journal-title":"Mechanisms of Ageing and Development"},{"issue":"1-4","key":"10.1002\/14651858.CD009081.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000335156","article-title":"Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease","volume":"10","author":"Atri","year":"2012","journal-title":"Neurodegenerative Diseases"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0058|cit58","first-page":"200","volume-title":"Measuring mental health needs","author":"Beecham","year":"2001"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1212\/01.wnl.0000266627.96040.5a","article-title":"Donepezil preserves cognition and global function in severe Alzheimer's disease patients","volume":"69","author":"Black","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/ageing\/25.2.113","article-title":"Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale","volume":"25","author":"Bucks","year":"1996","journal-title":"Age and Ageing"},{"issue":"7","key":"10.1002\/14651858.CD009081.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1368-5031.2005.00562.x","article-title":"Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years","volume":"59","author":"Bullock","year":"2005","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/gps.1746","article-title":"Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease","volume":"22","author":"Burns","year":"2007","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.b75","article-title":"Dementia","volume":"338","author":"Burns","year":"2009","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"M77","DOI":"10.1093\/geronj\/44.3.M77","article-title":"A description of agitation in a nursing home","volume":"44","author":"Cohen-Mansfield","year":"1988","journal-title":"Journal of Gerontology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD009081.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00702-006-0526-2","article-title":"Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment","volume":"113","author":"Darreh-Shori","year":"2006","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/156720510790274455","article-title":"Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies","volume":"7","author":"Darreh-Shori","year":"2010","journal-title":"Current Alzheimer Research"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3940(01)01586-5","article-title":"Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease","volume":"300","author":"Davidsson","year":"2001","journal-title":"Neuroscience Letters"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40266-015-0273-x","article-title":"The use of cholinesterase inhibitors across all stages of Alzheimer's disease","volume":"32","author":"Deardorff","year":"2015","journal-title":"Drugs and Aging"},{"issue":"1","key":"10.1002\/14651858.CD009081.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00002093-199903000-00008","article-title":"Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients","volume":"13","author":"Doody","year":"1999","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.58.3.427","article-title":"Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer Disease","volume":"58","author":"Doody","year":"2001","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0073|cit73","first-page":"1","article-title":"Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years","volume":"5","author":"Farlow","year":"2005","journal-title":"BMC Geriatrics"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/cns.12158","article-title":"A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg\/24 h versus 4.6 mg\/24 h in severe Alzheimer's Dementia","volume":"19","author":"Farlow","year":"2013","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/WAD.0000000000000073","article-title":"A 24-week open-label extension study to investigate the long-term safety, tolerability and efficacy of 13.3mg\/24h rivastigmine patch in patients with severe Alzheimer disease","volume":"29","author":"Farlow","year":"2015","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1212\/WNL.57.4.613","article-title":"A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease","volume":"57","author":"Feldman","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/gps.2141","article-title":"Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease","volume":"24","author":"Feldman","year":"2009","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-mental state: a practical method for grading the cognitive status of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000334991","article-title":"Memantine in everyday clinical practice: a comparison of studies in Germany and Greece","volume":"32","author":"F\u00f6rstl","year":"2011","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"5","key":"10.1002\/14651858.CD009081.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"Article ID e351","DOI":"10.1371\/journal.pone.0035185","article-title":"Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial","volume":"7","author":"Fox","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1017\/S1355617705050502","article-title":"Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease","volume":"11","author":"Galasko","year":"2005","journal-title":"Journal of the International Neuropsychological Society"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1046\/j.1365-2389.2003.51306.x","article-title":"Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease","volume":"51","author":"Geldmacher","year":"2003","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia","volume":"53","author":"Gelinas","year":"1999","journal-title":"The American Journal of Occupational Therapy"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/archinternmed.2009.43","article-title":"Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study","volume":"169","author":"Gill","year":"2009","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S0033291796004242","article-title":"The validity of two versions of the GHQ in the WHO study of mental illness in general health care","volume":"27","author":"Goldberg","year":"1997","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","article-title":"The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors","volume":"27","author":"Grossberg","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0087|cit87","first-page":"218","volume-title":"ECDEU Assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"5580","key":"10.1002\/14651858.CD009081.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"issue":"11","key":"10.1002\/14651858.CD009081.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/j.1532-5415.2009.02488.x","article-title":"Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system","volume":"57","author":"Hernandez","year":"2009","journal-title":"Journal of the American Geriatrics Society"},{"issue":"4","key":"10.1002\/14651858.CD009081.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jalz.2007.07.007","article-title":"Clinical practice guidelines for severe Alzheimer's disease","volume":"3","author":"Herrmann","year":"2007","journal-title":"Alzheimer's and Dementia"},{"issue":"10","key":"10.1002\/14651858.CD009081.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1532-5415.2007.01377.x","article-title":"A population-based study of cholinesterase inhibitor use for dementia","volume":"55","author":"Herrmann","year":"2007","journal-title":"Journal of the American Geriatrics Society"},{"issue":"12","key":"10.1002\/14651858.CD009081.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1503\/cmaj.070804","article-title":"Management of severe Alzheimer disease","volume":"179","author":"Herrmann","year":"2008","journal-title":"Canadian Medical Association Journal"},{"issue":"5","key":"10.1002\/14651858.CD009081.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/11588160-000000000-00000","article-title":"Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open label pilot study","volume":"25","author":"Herrmann","year":"2011","journal-title":"CNS Drugs"},{"issue":"S1","key":"10.1002\/14651858.CD009081.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/alzrt201","article-title":"Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012","volume":"5","author":"Herrmann","year":"2013","journal-title":"Alzheimer's Research &Therapy"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jagp.2017.10.014","article-title":"Cholinesterase inhibitor discontinuation: the buck stops here","volume":"26","author":"Herrmann","year":"2018","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0097|cit97","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"12","key":"10.1002\/14651858.CD009081.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/070674371405901202","article-title":"Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer Disease","volume":"59","author":"Hogan","year":"2014","journal-title":"Canadian Journal of Psychiatry"},{"issue":"15","key":"10.1002\/14651858.CD009081.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1517\/14656566.9.15.2575","article-title":"Pharmacological treatment in moderate-to-severe Alzheimer's disease","volume":"9","author":"Hsiung","year":"2008","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/gps.617","article-title":"Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version","volume":"17","author":"Iverson","year":"2002","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0101|cit101","volume-title":"Understanding dementia","author":"Jacques","year":"2000"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archinte.1996.00440050031004","article-title":"Lewy body disease and dementia","volume":"156","author":"Kalra","year":"1996","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1532-5415.1998.tb02542.x","article-title":"Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory caregiver Distress scale","volume":"46","author":"Kaufer","year":"1998","journal-title":"Journal of the American Geriatrics Society"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3233\/JAD-2011-110417","article-title":"Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study","volume":"27","author":"Kavanagh","year":"2011","journal-title":"Journal of Alzheimer's disease"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000113034","article-title":"Galantamine in frontotemporal dementia and primary progressive aphasia","volume":"25","author":"Kertesz","year":"2008","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"6","key":"10.1002\/14651858.CD009081.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1532-5415.2011.03450.x","article-title":"Dementia medications and risk of falls, syncope and related adverse events: meta-analysis of randomized controlled trials","volume":"59","author":"Kim","year":"2011","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/gps.4583","article-title":"Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's Disease (the DOMINO-AD trial)","volume":"32","author":"Knapp","year":"2017","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"s334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","article-title":"Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease","volume":"80","author":"Lopez","year":"2009","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-1781(91)90040-V","article-title":"Reliability and validity of the Apathy Evaluation Scale","volume":"38","author":"Marin","year":"1991","journal-title":"Psychiatry Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD009081.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3233\/JAD-2006-9S347","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy Bodies (DLB): report of the Consortium on DLB International Workshop","volume":"9","author":"McKeith","year":"2006","journal-title":"Journal of Alzheimer's Disease"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0113|cit113","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003154.pub6","article-title":"Memantine for dementia","author":"McShane","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"S2","key":"10.1002\/14651858.CD009081.pub2-BIB0114|cit114","first-page":"S13-21","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope.The Alzheimer's Disease Cooperative Study","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Disease and Associated Disorders"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.481","article-title":"A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients","volume":"57","author":"Mohs","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/153331750401900309","article-title":"Clinicopathological concordance of dementia diagnoses by community versus tertiary care clinicians","volume":"19","author":"Mok","year":"2004","journal-title":"American Journal of Alzheimer's Disease and Other Dementias"},{"issue":"1","key":"10.1002\/14651858.CD009081.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1176\/ajp.148.1.102","article-title":"Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination","volume":"148","author":"Molloy","year":"1991","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD009081.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1517\/14656566.2014.902446","article-title":"Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan","volume":"15","author":"Nakamura","year":"2014","journal-title":"Expert Opinion in Pharmacotherapy"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0120|cit120","unstructured":"National Institute for Health and Clinical Excellence Dementia: Supporting people with dementia and their carers in health and social care London (UK): National Institute for Health and Clinical Excellence; 2006. Clinical guideline [CG42]"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/156720509787313961","article-title":"Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients","volume":"6","author":"Nordberg","year":"2009","journal-title":"Current Alzheimer Research"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0140-6736(15)00463-8","article-title":"Vascular dementia","volume":"386","author":"O'Brien","year":"2015","journal-title":"Lancet Neurology"},{"issue":"11","key":"10.1002\/14651858.CD009081.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"e1424","DOI":"10.4088\/JCP.14r09237","article-title":"Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials","volume":"76","author":"O'Regan","year":"2015","journal-title":"Journal of Clinical Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD009081.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1000157","article-title":"Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study","volume":"6","author":"Park-Wyllie","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1007\/s100720200086","article-title":"Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors","volume":"23","author":"Parnetti","year":"2002","journal-title":"Neurological Sciences"},{"issue":"6","key":"10.1002\/14651858.CD009081.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/11536760-000000000-00000","article-title":"Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying?","volume":"27","author":"Parsons","year":"2010","journal-title":"Drugs and Aging"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/gps.4006","article-title":"Assessment of factors that influence physician decision making regarding medication use in patients with dementia at the end of life","volume":"29","author":"Parsons","year":"2014","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1468-1331.2004.00885.x","article-title":"Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial","volume":"11","author":"Pirttila","year":"2004","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0129|cit129","first-page":"553","article-title":"Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease","volume":"5","author":"Puangthong","year":"2009","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0130|cit130","volume-title":"Textbook of Psychiatry","author":"Puri","year":"2011"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-148-5-200803040-00008","article-title":"Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians","volume":"148","author":"Qaseem","year":"2008","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMra0909142","article-title":"Alzheimer's disease: mechanisms of disease","volume":"362","author":"Querferth","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD009081.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"379","DOI":"10.7326\/0003-4819-148-5-200803040-00009","article-title":"Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline","volume":"148","author":"Raina","year":"2008","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD009081.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00702-011-0623-8","article-title":"Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study","volume":"118","author":"Rainer","year":"2011","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0135|cit135","doi-asserted-by":"crossref","unstructured":"Reeve E Farrell B Thompson W Herrmann N Sketris I Magin P Evidence-based clinical practice guideline for deprescribing cholinesterase inhibitors and memantine Sydney (Australia). The University of Sydney, NHMRC Partnership Centre: Dealing with Cognitive and Related Functional Decline in Older People (Cognitive Decline Partnership Centre), Bruye\u0300re Research Institute, Deprescribing Guidelines in the Elderly Project; 2018 February","DOI":"10.5694\/mja2.50015"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0136|cit136","first-page":"653","article-title":"Functional assessment staging (FAST)","volume":"24","author":"Reisberg","year":"1988","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD009081.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archneur.63.1.49","article-title":"A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease","volume":"63","author":"Reisberg","year":"2006","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jagp.2017.09.027","article-title":"A systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia","volume":"26","author":"Renn","year":"2018","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD009081.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/gps.2165","article-title":"Ten years of cholinesterase inhibitors","volume":"24","author":"Rodda","year":"2009","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"e2986","key":"10.1002\/14651858.CD009081.pub2-BIB0140|cit140","first-page":"1","article-title":"Cholinesterase inhibitors and memantine for symptomatic treatment of dementia","volume":"344","author":"Rodda","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study","volume":"10","author":"Rogers","year":"2000","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0142|cit142","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006504.pub2","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease","author":"Rolinski","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/alzrt7","article-title":"Persistent treatment with cholinesterase inhibitors and\/or memantine slows clinical progression of Alzheimer disease","volume":"1","author":"Rountree","year":"2009","journal-title":"Alzheimer's Research & Therapy"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jalz.2012.01.002","article-title":"Effectiveness of antidementia drugs in delaying Alzheimer's disease progression","volume":"9","author":"Rountree","year":"2013","journal-title":"Alzheimer's and Dementia"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jamda.2013.01.010","article-title":"Two cases of loss of consciousness after long-term memantine treatment","volume":"14","author":"Savic","year":"2013","journal-title":"Journal of the American Medical Directors Association"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1037\/1040-3590.2.3.298","article-title":"Assessment of the severely impaired patient: description and validation of a new neuropsychological Test Battery","volume":"2","author":"Saxton","year":"1990","journal-title":"Psychological Assessment: A Journal of Consulting and Clinical Psychology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer's Disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0149|cit149","first-page":"158","article-title":"A systematic review of assessment and treatment of moderate to severe Alzheimer's disease","volume":"8","author":"Schmitt","year":"2006","journal-title":"Primary Care Companion to the Journal of Clinical Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD009081.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer Diease and Associated Disorders"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3233\/JAD-2011-101929","article-title":"Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial","volume":"25","author":"Schulz","year":"2011","journal-title":"Journal of Alzheimer's Disease"},{"issue":"8","key":"10.1002\/14651858.CD009081.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamainternmed.2015.0324","article-title":"Reducing inappropriate polypharmacy: the process of deprescribing","volume":"175","author":"Scott","year":"2015","journal-title":"JAMA Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD009081.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2165\/00002512-200724110-00001","article-title":"Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?","volume":"24","author":"Seltzer","year":"2007","journal-title":"Drugs & Aging"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF03325164","article-title":"Memantine in Alzhiemer's disease: experience in an Alzheimer's disease assessment unit","volume":"24","author":"Sinforiani","year":"2012","journal-title":"Aging Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1368-5031.2005.00524.x","article-title":"Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years","volume":"59","author":"Small","year":"2005","journal-title":"International Journal of Clinical Practice"},{"issue":"10","key":"10.1002\/14651858.CD009081.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9100","article-title":"Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology","volume":"9","author":"Smith","year":"2005","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3346\/jkms.2008.23.1.10","article-title":"Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study","volume":"23","author":"Jung","year":"2008","journal-title":"Journal of Korean Medical Science"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/2051-5960-1-65","article-title":"Clinical and multimodal biomarker correlates of ADNI neuropathological findings","volume":"1","author":"Toledo","year":"2013","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S0033291700055549","article-title":"Plaques, tangles and Alzheimer's disease","volume":"12","author":"Tomlinson","year":"1982","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1017\/S0033291713000494","article-title":"The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies","volume":"44","author":"Vann Jones","year":"2014","journal-title":"Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/0002512-200926020-00005","article-title":"Diagnosis and Treatment of Patients with Severe Alzheimer's Disease","volume":"26","author":"Voisin","year":"2009","journal-title":"Drugs & Aging"},{"issue":"2","key":"10.1002\/14651858.CD009081.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09638288809164105","article-title":"The Barthel ADL Index: a standard measure of physical disability?","volume":"10","author":"Wade","year":"1988","journal-title":"International Disability Studies"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","article-title":"Lewy body dementias","volume":"386","author":"Walker","year":"2015","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD009081.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/WAD.0b013e3181f5dd97","article-title":"Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment","volume":"25","author":"Wattmo","year":"2011","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0166|cit166","first-page":"114","article-title":"The quality of life in late-stage dementia (QUALID) scale","volume":"1","author":"Weiner","year":"2000","journal-title":"Journal of the American Medical Directors Association"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4088\/JCP.v69n0302","article-title":"Memantine for agitation\/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies","volume":"69","author":"Wilcock","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1212\/WNL.57.3.489","article-title":"A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD","volume":"57","author":"Winblad","year":"2001","journal-title":"Neurology"},{"issue":"S2","key":"10.1002\/14651858.CD009081.pub2-BIB0169|cit169","first-page":"293","article-title":"Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's Disease: results from a one-year placebo-controlled study and two-year follow-up study","volume":"15","author":"Winblad","year":"2003","journal-title":"International Psychogeriatrics"},{"issue":"S1","key":"10.1002\/14651858.CD009081.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/01.wad.0000127495.10774.a4","article-title":"Long-term treatment of Alzheimer Disease: efficacy and safety of acetylcholinesterase inhibitors","volume":"18","author":"Winblad","year":"2004","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"9516","key":"10.1002\/14651858.CD009081.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(06)68350-5","article-title":"Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study","volume":"367","author":"Winblad","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1159\/000091790","article-title":"3-Year Study of Donepezil Therapy in Alzheimers Disease: Effects of Early and Continuous Therapy","volume":"21","author":"Winblad","year":"2006","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"S1","key":"10.1002\/14651858.CD009081.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1041610206004017","article-title":"Severe Alzheimer's disease: benefits of donepezil therapy","volume":"18","author":"Winblad","year":"2006","journal-title":"International Psychogeriatrics"},{"issue":"3","key":"10.1002\/14651858.CD009081.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1533317509332094","article-title":"Review: Donepezil in Severe Alzheimer's Disease","volume":"24","author":"Winblad","year":"2009","journal-title":"American Journal of Alzheimer's Disease and Other Dementias"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer's disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0176|cit176","volume-title":"International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Version for 2010","author":"World Health Organization","year":"2010"},{"issue":"1","key":"10.1002\/14651858.CD009081.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S1474-4422(15)00092-7","article-title":"Dementia in western Europe: epidemiological evidence and implications for policy making","volume":"15","author":"Wu","year":"2016","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ageing\/afi190","article-title":"A systematic review of prevalence and incidence studies of dementia with Lewy bodies","volume":"34","author":"Zaccai","year":"2005","journal-title":"Age and Ageing"},{"key":"10.1002\/14651858.CD009081.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jalz.2012.09.015","article-title":"Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease","volume":"9","author":"Zhu","year":"2013","journal-title":"Alzheimer's and Dementia"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T15:05:38Z","timestamp":1683126338000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009081.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":179,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009081.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]}}}